Scott Koenig increases MacroGenics (MGNX) stake via 15,831 RSU conversion

Rhea-AI Filing Summary

MacroGenics director Scott Koenig converted 15,831 restricted stock units into an equal number of MacroGenics common shares on February 8, 2026, at an exercise price of $0 per share. After this conversion, he directly owned 846,075 shares of common stock and 15,832 RSUs.

The RSUs come from a 95,000-unit grant on February 8, 2024. One-third vested after one year, and half of the remaining units vested under a Separation Agreement on August 13, 2025. The rest vest in two equal annual installments on the grant anniversary.

Insider Trade Summary

15,831 shares exercised/converted

Mixed 2 txns

Insider Koenig Scott

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	15,831	$0.00	--
Exercise	Common Stock	15,831	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 15,832 shares (Direct); Common Stock — 846,075 shares (Direct)

Footnotes (1)

1. Restricted stock units convert into the Company's stock on a one-for-one basis. On February 8, 2024, the reporting person was granted 95,000 restricted stock units. One-third of the restricted stock units vested after one year and one-half of the remaining units vested pursuant to the reporting person's "Separation Agreement" on August 13, 2025. The remaining units vest in two equal installments on the anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koenig Scott

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/08/2026		M		15,831	A	(1)	846,075	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/08/2026		M			15,831	(2)	(2)	Common Stock	15,831	$0	15,832	D

Explanation of Responses:

1. Restricted stock units convert into the Company's stock on a one-for-one basis.

2. On February 8, 2024, the reporting person was granted 95,000 restricted stock units. One-third of the restricted stock units vested after one year and one-half of the remaining units vested pursuant to the reporting person's "Separation Agreement" on August 13, 2025. The remaining units vest in two equal installments on the anniversary of the grant date.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MacroGenics (MGNX) report for Scott Koenig?

MacroGenics reported that director Scott Koenig converted 15,831 restricted stock units into common stock on February 8, 2026. The RSUs converted one-for-one into shares at an exercise price of $0 per share, with no sale disclosed.

How many MacroGenics (MGNX) shares does Scott Koenig own after this Form 4?

After the reported transaction, Scott Koenig directly owned 846,075 shares of MacroGenics common stock. In addition, a remaining 15,832 restricted stock units were beneficially owned, which may convert into common shares as their vesting schedule is completed.

Were any MacroGenics (MGNX) shares sold in Scott Koenig’s latest Form 4?

The filing shows a code M transaction, meaning 15,831 restricted stock units were converted into common shares at $0 per share. It does not report any sale transaction; it only reflects RSU conversion and updated share ownership.

What is the origin of the 15,831 RSUs reported for MacroGenics (MGNX)?

The 15,831 RSUs are part of a 95,000-unit restricted stock grant awarded on February 8, 2024. One-third vested after one year, additional units vested under a Separation Agreement, and remaining units vest in two equal future annual installments.

How do the MacroGenics (MGNX) restricted stock units convert into shares?

The filing states that restricted stock units convert into MacroGenics stock on a one-for-one basis. Each RSU becomes one share of common stock upon vesting and settlement, as reflected in the 15,831 RSUs converting into 15,831 shares on February 8, 2026.

What does the Separation Agreement mentioned in the MacroGenics (MGNX) Form 4 affect?

The Separation Agreement caused one-half of the remaining RSUs from the original 95,000-unit grant to vest on August 13, 2025. The filing notes this accelerated vesting, while the final unvested RSUs vest in two equal annual installments on the grant anniversary.